RRx-001

• UNSPSC Description:

  RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity[1]. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α[2]. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity[3].

• Target Antigen:

  Apoptosis; CD47; Parasite

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Apoptosis;Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/RRx-001.html

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  BrCC(N1CC([N+]([O-])=O)([N+]([O-])=O)C1)=O

• Molecular Weight:

  268.02

• References & Citations:

  [1]Das DS, et al. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia. 2016 Nov;30(11):2187-2197.|[2]Cabrales P, et al. RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages. Transl Oncol. 2019 Apr;12(4):626-632.|[3]Yalcin O, et al. From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. Malar J. 2015 May 28;14:218.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 3

• CAS Number:

  925206-65-1